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ABSTRACT
The primary cause of death (COD) provides important information in many studies of hematopoietic stem cell
transplantation (HSCT). A panel of experts critically assessed theCODs submitted by 15 transplantation centers
for 281 patients who died in a randomized multicenter trial of unrelated HSCT. The panel reviewed the CODs
reported by the transplantation centers, which used the Center for International Blood andMarrow Transplant
Research and National Marrow Donor Program COD reporting form. The panel determined that the existing
criteria for primary and contributing CODs lacked sufficient stringency for uniform interpretation. A hierarchy
was developed and applied to the T cell depletion project. Using its scheme, the panel reclassified 157 CODs
(56%) reported by the transplantation centers. The changes resulted in increased recognition of graft-versus-
host disease as the primary COD and a concomitant decrease in attribution of the primary COD to infection.
This algorithm promotes consistent assignment of primary and contributing CODs for patients with leukemia
or lymphoma who expire after myeloablative allogeneic HSCT.
 2007 American Society for Blood and Marrow Transplantation
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The cause of death (COD) provides important in-
formation on many patient cohorts, including those
participating in clinical studies of hematopoietic stem
cell transplantation (HSCT). Analysis of COD data
can help identify problems, modify clinical behavior,
and guide new studies.
Clinical studies of HSCT commonly report COD.
The standard form (Form 190) from the Center for In-
ternational Blood and Marrow Transplant Research
and National Marrow Donor Program (CIBMTR/
NMDP) lists common causes but provides limited
guidance to distinguish among competing CODs,such as graft-versus-host disease (GVHD) and infec-
tion. Differences in reporting practices compromise
clinical studies of HSCT and prevent reliable compar-
isons of results between studies.
COD was an important component of a large
prospective multicenter trial of unrelated donor
HSCT in which recipients were randomized to receive
unmodified marrow and posttransplantation immuno-
suppression with methotrexate (MTX) and cyclospor-
ine (CSA) or T cell–depleted (TCD) marrow and
posttransplantation immunosuppression with CSA
alone for prevention of GVHD [1]. The primary ob-
jective of this TCD trial was to compare the 3-year dis-
ease-free survival (DFS) of the 2 groups; secondary1469
1470 E. Copelan et al.objectives included comparisons of (1) overall survival
(OS), (2) relapse, (3) engraftment, (4) severity and inci-
dence of GVHD, (5) severity and incidence of infec-
tions, and (6) regimen-related toxicity and adverse
events. The CODs were reported by transplantation
centers using CIBMTR/NMDP COD codes. The re-
ported CODs were then reviewed by an expert panel
with access to relevant medical records, including in-
fectious complications that had been reviewed and
audited by a panel of experts in this area. The COD
panel recognized substantial variation between centers
in assigning primary CODs. The panel used the same
primary COD list from CIBMTR/NMDP Form 190
but defined a hierarchy for determination of COD,
and then applied this scheme to the study patients.
METHODS
Patients
A total of 410 patients with lymphohematopoietic
malignancies were randomized to receive TCD mar-row and CSA after transplantation (TCD arm; n 5
203) or unmodified marrow with MTX and CSA
(M/C arm; n 5 207) for GVHD prophylaxis. The
method used for T-cell depletion was elutriation in
67 patients and monoclonal antibody (mAb) and com-
plement lysis in 136 patients. Accrual occurred be-
tween March 1995 and October 2000 at 15 centers in
theUnited States.Minimum follow-upwas 18months.
Institutional review board approval was obtained from
each center. Written consent was obtained from each
patient or legal guardian before randomization. The
cutoff date for analysis was April 2002.
Infection Prophylaxis
For transplantation, patients were hospitalized in
single reverse-isolation rooms. Each center had guide-
lines for preventing fungal infections, herpes simplex
and zoster virus reactivation, Pneumocystis pneumonia
and cytomegalovirus (CMV) reactivation after engraft-
ment, and infection with encapsulated Gram-positive
organisms during treatment of GVHD.Primary Disease Recurrence 
If death is due to relapse or 
persistent disease, this will 
be the primary cause of 
death.  
Report relapse as a contributing
cause of death.  
Non-Engraftment 
Graft failure is the 
primary cause of death if 
one of the following 3 
conditions is present. *Autologous recovery 
*Rejection: ANC sustained >500/mm3 more than 
three  consecutive days with subsequent decrease  
to <500/mm3 and bone marrow examinations, if
performed with <5% cellularity.  Rejection is the 
primary cause of death if the ANC decrease is not
attributable to other causes and host cells re-
appear that are not indicative of relapse.   
Must also list a secondary cause of
death
GVHD 
Acute GVHD  is the primary cause 
of death if patient was on treatment 
(not prophylaxis) for GVHD even 
if clinical GVHD not evident at
death 
Chronic GVHD is the primary cause 
of death if patient was receiving 
treatment for chronic GVHD even if
chronic GVHD not evident at death. 
For patients with acute GVHD prior to day +28 
and treated systemically, who also experience 
primary graft failure, acute GVHD will be the 
primary cause of death. 
If there is an intervention and patient gets GVHD, 
then the reason for the intervention is the primary
cause of death.  
Yes 
No
Recurrent disease was only
discovered by autopsy 
No
Yes
Primary graft failure: ANC <500/mm3 and bone
marrow examination, if performed, with <5%
cellularity during first 28 days.  
Condition 1 
Condition 2 
Condition 3 
No
Yes Prior to
day +28  
Figure 1. Hierarchy for COD.
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Separate panels reviewedweeklyGVHDstaging as-
sessments and infections. The acute GVHD (aGVHD)
panel developed a computer algorithm using the con-
sensus grading scheme [2]. GVHD occurring before
day 100 was classified as acute, and that occurring af-
ter day 100 was classified as chronic. The infection
review panel developed an algorithm to categorize in-
fection and tallied the numbers of severe, life-threat-
ening, and fatal infections per patient. A severity level
of fatal was assigned if the infection was present at the
time of death or if it contributed significantly to
death.
After the aGVHD and infection review panels
completed their evaluations, an expert panel composed
of 6 transplantation physicians, an infectious disease
specialist, and a statistician reviewed the COD reports
for every patient during weekly conference calls over
a 10-month period after the close of the study. The
COD form used by the CIBMTR/NMDP (Form
190) served as the template for reporting COD bythe transplantation center. Autopsy records were re-
viewed. The panel was blinded to treatment arm.
For every patient, the panel reviewed a demo-
graphic summary that included age, disease, and
disease stage; days to neutrophil and platelet engraft-
ment and chimerism results; maximum organ toxicity
within 28 days of transplantation using the Bearman
scale [3]; posttransplantation complications, such
as bronchiolitis obliterans organizing pneumonia
(BOOP), adult respiratory distress syndrome (ARDS),
and veno-occlusive disease; weekly aGVHD scoring
records; presence and stage of chronic GVHD
(cGVHD); immunosuppressive medications at the
time of death; documentation of relapse; all infections,
including dates and severity; and the transplantation
center–designated COD. The COD was assigned by
reaching consensus on a conference call through case
presentation and discussion.
A flow diagram illustrating the hierarchy devel-
oped by the panel for assigning primary and contribut-
ing CODs is depicted in Figure 1. If relapse occurred,Infection 
Protozoal 
Fungal 
Bacterial 
Viral 
Report viral pneumonia and viral infection of other organs as
infectious interstitial pneumonia. 
Organ Failure 
Report any organ 
failure that is not due 
to GVHD or infection.
Multi-organ failure is 
defined as failure of 
more than 1 organ 
system. The hierarchy
for single organ 
failures:  
1st – Secondary graft 
failure 
2nd - Other, multi-
organ failure 
3rd – Pulmonary 
4th – Cardiac 
5th – Liver 
6th – Renal 
7th – Central nervous 
system 
Secondary graft failure 
No
No
EBV should be listed here even if patient developed lymphoma 
Yes 
ARDS  or non-infectious pulmonary organ failure, if clearly following a 
precipitating event such as bacterial sepsis, severe, transfusion reaction or 
other systemic insult. Yes 
Other: Multi-organ failure, hepatorenal syndrome, hemorrhagic
cystitis, gastrointestinal injuries, acute or chronic pancreatitis 
Pulmonary: Organizing alveolitis, diffuse alveolar hemorrhage, 
pulmonary hypertension, pneumothorax, pulmonary fibrosis, 
aspiration pneumonia, non-infectious acute respiratory failure 
occurring <28 days after transplantation, non-infectious acute 
respiratory failure occurring one month or more post-transplant 
that does not meet the criteria for ARDS
Cardiac: Heart failure, congestive heart failure, non-infectious 
pericarditis, cardiac tamponade 
Liver: Veno-occlusive disease, drug toxicities, non-infectious 
hepatitis, idiopathic hyperammonemic syndrome 
Renal: Uremic coma, chronic or acute renal failure 
Central nervous system: Radiation-induced brain atrophy, strokes 
or infarcts, brain stem dysfunction, encephalitis of unknown 
origin, cerebritis 
Figure 1. (continued)
1472 E. Copelan et al.then this was assigned as the primary COD. Primary
graft failure was defined as failure to achieve an abso-
lute neutrophil count (ANC) of 500/mm3 by day 28 af-
ter transplantation. For patients who died before day
14 after transplantation, graft failure was not listed as
the primary COD. For patients with aGVHD who re-
quired systemic immunosuppressive therapy before
day 28 after transplantation and also experienced pri-
mary graft failure, aGVHD was identified as the pri-
mary COD, with graft failure as the secondary COD.
Patients with a primary COD of either graft failure
or GVHD had contributing causes (eg, infection, or-
gan failure) recorded as secondary or tertiary. If re-
lapse, graft failure, or GVHD were present at the
time of death, then this was assigned as the primary
COD. In this setting, infections and organ failure
were recorded as secondary and tertiary CODs. If re-
lapse was detected at autopsy for the first time, then re-
lapse was recorded as a secondary COD rather than as
the primary COD.
If none of the aforementioned causeswere recorded
as the primary COD, then the algorithm continued
with infection and organ failure, according to Figure 1.
Statistical Analysis
All contingency tables and c2 tests were performed
using SAS version 8.2 (SAS Institute, Cary, NC).RESULTS
Patients
Of the 410 patients, 5 died before undergoing trans-
plantation. Seven patients assigned to receive TCD re-
ceived M/C instead, because of low cell dose (n 5 5),
logistics of total body irradiation (n 5 1), or complica-
tions of the conditioning regimen (TBI; n5 1). Except
for infused cell dose, baseline characteristics were simi-
lar for the 2 treatment arms (data not shown) [1].
Primary COD
Death occurred in 141 of the 203 TCD patients
(69%) and in 140 of the 207 M/C patients (68%). A
total of 70 patients were autopsied. In 56% of the
patients, the primary COD assigned by the reporting
transplantation center was changed by the review
panel, using the diagram shown in Figure 1. The
difference between treatment arms in the number of
patients whose primary COD was changed was not
statistically significant (57% for the TCD group and
54% for the unmodified group).
For the 157 patients in whom a change was made,
the differences between the primary COD assigned
by the panel and that reported by the transplantation
center are shown in Table 1. Determination that
aGVHD (n 5 48) or cGVHD (n 5 41) was theReport secondary malignancies, but not EBV lymphoma
Report hemorrhage when there is excessive bleeding, typically from the gastrointestinal tract
or a ruptured blood vessel, not the central nervous system 
Report accidental death for accidents that are unrelated to the medical treatment of the  patient.
These include motor vehicle accidents, falls, drownings, natural disasters, etc.  
Report other when all other categories above do not describe the primary or contributing 
cause of death for such instances as suicide, heart attack, cardiac arrest, ventricular 
tachyarrhythmia, malignant arrhythmia, cardiopulmonary arrest, sudden death, and death 
from progressive nonmalignant disease (e.g., a persistent or recurrent metabolic disorder, 
such as Hurler Syndrome).
Secondary Malignancies 
Hemorrhage
Accidental Death 
Other 
No
No
No
Yes
Yes
Yes 
Yes 
Figure 1. (continued)
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) primary COD accounted for the majority of the
changes.
GVHD (acute, 24%; chronic, 19%) was the most
common COD designated by the panel. There was
no difference in the incidence of aGVHD as the pri-
mary COD (TCD, 22%; M/C, 26%) between treat-
ment arms, although the incidence of grade III/IV
aGVHD differed significantly between treatment
arms (TCD, 18% vs M/C, 37%; P\ .001) [1]. The in-
cidence of cGVHD as the primary COD was not dif-
ferent by treatment arm (TCD, 18% vs M/C, 19%)
[4]. The secondary causes of death for patients in
whom GVHD was the primary COD are given in
Table 2. There were no significant differences between
treatment arms. Viral infections accounted for 4% of
the primary CODs in both treatment arms; however,
viral infections after transplantation were more com-
mon in the TCD arm [2]. There was no difference be-
tween the treatment arms for any of the primary CODs
(Table 3).
Notable modifications to the assigned primary
COD after panel review occurred with assignment of
6 cases of relapse, 2 cases of persistent disease, 15 cases
of primary graft failure, 51 cases of aGVHD, and 41
cases of cGVHD. There were no differences by treat-
ment arm.
Comparison With Causes of Death Reported
to the CIBMTR
Figure 2 compares the primary CODs reported to
the CIBMTR for 2896 patients undergoing unrelated
donor transplantation during a similar time period, in-
cluding patients who received TCD grafts. The form
for reporting COD was the same as that used by the
transplantation centers in this trial. The pie charts
for the CIBMTR data (A) are nearly identical to the
CODs reported by transplantation centers in this trial
(B); the revised assignment based on the hierarchy de-
veloped by the COD committee (C) differs markedly.
Notable findings include increases in GVHD as the
primary COD (with a concomitant decrease in infec-
tion) and the almost complete absence (1 case) of idio-
pathic pneumonia (IP) as the primary COD.
DISCUSSION
Despite its recognized importance, stringent rules
for assignment of COD after myeloblativeHSCThave
not been developed. Guidance is required because
multiple factors often contribute to death after alloge-
neic transplantation [5,6]. The immediate COD may
directly result from a condition (eg, graft failure,
GVHD) that is responsible for the fatal outcome. In-
consistencies in the designation of COD by individual
investigators and between investigators and centers is
problematic. Figure 2 illustrates that the COD
1474 E. Copelan et al.designated by the centers in this trial reflects that for all
patients reported to the CIBMTR.
This report describes the development and use of
a scheme for determining COD in patients with lym-
phohematopoietic malignancies who underwent mye-
loablative conditioning and unrelated transplantation.
Data were collected prospectively from multiple
transplantation centers and audited for primary and
secondary CODs, weekly GVHD assessments, and
documentation of all infectious episodes. In a majority
of patients, the COD reported by the transplantation
centers was reassigned by the review panel. The newly
designated primary COD and the number of changes
were similar between the 2 treatment arms.
Recurrence or persistence of underlying hemato-
logic disease is given precedence. In the proposed
schema, a patient who relapses, receives additional
treatment, and dies of a fungal infection is assigned re-
currence of disease as the primary COD. Fungal infec-
tion is considered a secondary cause.
If there is no evidence of relapse, graft failure is the
next most important cause, followed by GVHD. The
pie charts in Figure 2 illustrate that the application of
this series of rules resulted in a significant shift between
the primary COD reported by the transplantation cen-
ters and the final decision reached by the review panel,
particularly as related to GVHD. In a patient who died
while receiving treatment for GVHD, GVHD was as-
signed as the primary COD, even if there was no clini-
cal evidence of GVHD. GVHD was also the primary
COD for patients who were treated for GVHD before
day 28 and experienced primary graft failure.
Interstitial pneumonitis (IP) with a known under-
lying infectious cause was reclassified as an infection,
whereas historically the CIBMTR would not list
CMV IP as infection. This resulted in a decreased
Table 2. Secondary COD by treatment in patients in whom the primary
COD was GVHD
TCD
(n 5 141)
Unmodified
(n 5 140)
Total
(n 5 281)
Primary COD n (%) n (%) n (%)
Acute GVHD
Secondary CODs 31 (22) 36 (26) 67 (24)
Primary graft failure 0 1 1
Infection 26 18 44
Organ failure 3 9 12
Hemorrhage 0 1 1
None 2 7 9
Chronic GVHD
Secondary CODs 26 (18) 27 (19) 53 (19)
Infection 12 13 25
Organ failure 2 2 4
Secondary malignancy 1 0 1
Other 2 1 3
None 9 11 20number of primary CODs attributed to IP.We recom-
mend that IP should represent ‘‘idiopathic’’ rather than
‘‘interstitial’’ pneumonitis, because ‘‘interstitial’’ may
include viral infections.
This hierarchy was developed for myeloablative
HSCT, particularly for patients with leukemia or lym-
phoma. It has been used to analyze data obtained from
the Cord Blood Transplantation (COBLT) study
[7-9]. Modified hierarchies for reporting primary
CODs might be considered in other settings.
Correct delineation of the primary COD is impor-
tant. The growing number of multi-institutional trials
increases the need for uniform standards. The rules
proposed herein encourage uniformity in the assign-
ment of COD. This refined hierarchy places more im-
portance on conditions preceding and responsible for
the immediate COD and allows for prioritization of
multiple problems. A similar approach has proved
useful in other conditions; for example, an algorithm
favoring linkage of human immunodeficiency virus/ac-
quired immunodeficiency syndrome to COD proved
Table 3. Primary COD by treatment
TCD
(n 5 141)
Unmodified
(n 5 140)
Total
(n 5 281)
Primary COD n (%) n (%) n (%)
Recurrence/relapse 31 (22) 30 (21) 61 (22)
Persistent disease 2 (1) 0 (0) 2 (1)
Graft failure
Primary 8 (6) 12 (9) 20 (7)
Autologous recovery 1 (1) 0 (0) 1 (0)
Rejection 1 (1) 0 (0) 1 (0)
GVHD
Acute 31 (22) 36 (26) 67 (24)
Chronic 26 (18) 27 (19) 53 (19)
Infection
Fungal 5 (4) 2 (1) 7 (2)
Bacterial 1 (1) 3 (2) 4 (1)
Viral 6 (4) 5 (4) 11 (4)
Other1 6 (4) 3 (2) 9 (3)
Organ failure
Other2 4 (3) 8 (6) 12 (4)
Pulmonary 8 (6) 4 (3) 12 (4)
Non-ARDS 3 2 5
ARDS 5 2 7
Cardiac 4 (3) 1 (1) 5 (2)
Liver 1 (1) 2 (1) 3 (1)
Secondary graft
failure
2 (1) 2 (1) 4 (1)
Secondary malignancy 0 (0) 1 (1) 1 (0)
Hemorrhage 3 (2) 1 (1) 4 (1)
Other3 1 (1) 3 (2) 4 (1)
1Infection – Other: TCD, n 5 6; polyorganism, unmodified, n 5 2;
polyorganism, n 5 1: Polymicrobial.
2Organ Failure – Other: TCD, N51: Guillain-Barre Syndrome,
N53: Multi-Organ Failure; Unmodified, N57: Multi-Organ
Failure, N51: Pulmonary.
3Other TCD,N51: TTP/HUS; Unmodified,N51: unknown, n51
myocardial infarction, n51 cardiac.
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25%
14%
9%
21%
15%
12%
22%
19%
6%
20%
21%
43%
22%
13%
11%
11%
GVHD
Relapse
Organ Toxicity
IPn
Infection
Other
CIBMTR1
1996 – 2000
2896 Deaths 
T-Cell Depletion Trial
1995 – 2002
281 Deaths   
Transplant Center Reported2,4 Review Committee3,4
1 This is a preliminary review of information submitted to the Statistical Center of the Center for International Blood
and Marrow Transplant Research (CIBMTR). The analysis has not been reviewed or approved by the Advisory or
Scientific Committee of the CIBMTR.   
2p-value comparing to CIBMTR is 0.01 
3p-value comparing to CIBMTR is <0.0001 
4p-value comparing to Transplant Center and reviewer is <0.0001 
Figure 2. COD after unrelated donor transplantation.important in recognizing the effectiveness of antiretro-
viral therapy [10]. The specificity of the scheme pro-
motes consistency between different physicians and
centers, permitting greater accuracy and reliable com-
parisons of data. Inaccurate reporting of the primary
COD can lead to false assumptions and compromise
future trials. It is important for the transplantation
community to accept and incorporate a defined set of
rules defining COD for future trials.
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